3
Participants
Start Date
April 30, 2010
Primary Completion Date
July 31, 2011
Study Completion Date
July 31, 2011
CDX-1307 Vaccine Regimen
CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)
Chemotherapy
Weill Cornell Medical College, New York
SUNY Upstate Medical University, Syracuse
Syracuse VA Medical Center, Syracuse
Roswell Park Cancer Center, Buffalo
University of Rochester, Rochester
Thomas Jefferson University, Philadelphia
University of Maryland Greenebaum Cancer Center, Baltimore
University of Florida, Gainesville
Moffitt Cancer Center, Tampa
Henry Ford Health System, Detroit
University of Iowa Hospitals and Clinics, Iowa City
Washington University School of Medicine, St Louis
University of Colorado Cancer Center, Aurora
BCG Oncology, PC, Phoenix
University of Southern California Norris Comprehensive Cancer Center LA-USC Medical Center, Los Angeles
University of California - San Diego, La Jolla
University of Kentucky Markey Cancer Center Clinical Research Organization, Lexington
Lead Sponsor
Celldex Therapeutics
INDUSTRY